Citations

Clear

966 citation(s) found for "WONG, R".

Neurostimulation in people with drug‐resistant epilepsy: Systematic review and meta‐analysis from the ILAE Surgical Therapies Commission
Touma, Lahoud , Dansereau, Bénédicte, Chan, Alvin Y. , Jetté, Nathalie , Braun, Kees P. J. , Jehi, Lara , Rolston, John D. , Vadera, Sumeet, Englot, Dario J. , Keezer, Mark R. , Kwon, Churl-Su , Jehi, Lara , Rolston, John D , Wong-Kisiel, Lily C. , Englot, Dario J , Keezer, Mark R , Jette, Nathalie , Friedman, Daniel, Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia | March 30, 2022 | Volume: 63 | Issue: 6 | Pages: 1314-1329

10.1111/epi.17243 | PMID 35352349 Get It

AbstractObjectiveSummarize the current evidence on efficacy and tolerability of vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) through a systematic review and meta‐analysis.MethodsWe followed the Preferred Reporting Items of Systematic reviews and Meta‐Analyses reporting standards and searched Ovid Medline, Ovid Embase, and the Cochrane Central Register of Controlled Trials. We included published randomized controlled trials (RCTs) and their corresponding open‐label extension studies, as well as prospective case series, with ≥20 participants (excluding studies limited to children). Our primary outcome was the mean (or median, when unavailable) percentage decrease in frequency, as compared to baseline, of all epileptic seizures at last follow‐up. Secondary outcomes included the proportion of treatment responders and proportion with seizure freedom.ResultsWe identified 30 eligible studies, six of which were RCTs. At long‐term follow‐up (mean 1.3 years), five observational studies for VNS reported a pooled mean percentage decrease in seizure frequency of 34.7% (95% confidence interval [CI]: −5.1, 74.5). In the open‐label extension studies for RNS, the median seizure reduction was 53%, 66%, and 75% at 2, 5, and 9 years of follow‐up, respectively. For DBS, the median reduction was 56%, 65%, and 75% at 2, 5, and 7 years, respectively. The proportion of individuals with seizure freedom at last follow‐up increased significantly over time for DBS and RNS, whereas a positive trend was observed for VNS. Quality of life was improved in all modalities. The most common complications included hoarseness, and cough and throat pain for VNS and implant site pain, headache, and dysesthesia for DBS and RNS.SignificanceNeurostimulation modalities are an effective treatment option for drug‐resistant epilepsy, with improving outcomes over time and few major complications. Seizure‐reduction rates among the three therapies were similar during the initial blinded phase. Recent long‐term follow‐up studies are encouraging for RNS and DBS but are lacking for VNS.
Acute-on-Chronic Liver Failure
Bajaj, Jasmohan S. , Kamath, Patrick S. , O’Leary, Jacqueline G. , Wong, Florence , Lai, Jennifer C.

Mayo Clinic

American Journal of Gastroenterology | March 25, 2022 | Volume: 117 | Issue: 6 | Pages: 831-834

10.14309/ajg.0000000000001748 | PMID 35333779 Get It

Collaboration and Shared Decision-Making Between Patients and Clinicians in Preventive Health Care Decisions and US Preventive Services Task Force Recommendations
Force, US Preventive Services Task, Davidson, Karina W. , Mangione, Carol M. , Nicholson, Wanda K. , Cabana, Michael D. , Caughey, Aaron B. , Davis, Esa M. , Donahue, Katrina E , Kubik, Martha , Li, Li , Ogedegbe, Gbenga, Silverstein, Michael, Stevermer, James , Tseng, Chien‐Wen , Wong, John B. , Doubeni, Chyke A. , Davidson, Karina , Force, US Preventive Services Task, Barry, Michael J. , Pbert, Lori A.

Mayo Clinic

JAMA | March 22, 2022 | Volume: 327 | Issue: 12 | Pages: 1171

10.1001/jama.2022.3267 | PMID 35315879 Get It

Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
Iovleva, Alina , Mustapha, Mustapha M. , Griffith, M. Patrick , Komarow, Lauren , Luterbach, Courtney , Evans, Daniel R. , Cober, Eric , Richter, Sandra S. , Rydell, Kirsten, Arias, César A. , Jacob, Jesse T. , Salata, Robert A. , Satlin, Michael J. , Wong, Darren , Tyne, Daria Van , Doi, Yohei , Bonomo, Robert A , van Duin, David , Cooper, Vaughn S , Van Tyne, Daria , Doi, Yohei , Jacob, Jesse T , Griffith, Marissa P., Arias, César A. , Bonomo, Robert A.

Mayo Clinic

mBio | March 21, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.02759-21 | PMID 35311529 Get It

Carbapenem-resistant Acinetobacter baumannii (CR Ab ) constitutes a major threat to public health. To elucidate the molecular and clinical epidemiology of CR Ab in the United States, clinical CR Ab isolates were collected along with data on patient characteristics and outcomes, and bacterial isolates underwent whole-genome sequencing and antibiotic susceptibility phenotyping.
Abstract 10960: Genetic Overlap of Acute Myocarditis and Inherited Cardiomyopathy
Salmi, Sara, Meena, Devendra, Iacob, Alma, Jones, Richard W. , Wage, Rick, Yazdani, Momina , Wong, Joyce , Baksi, John, Pantazis, Antonios , Prasad, Sanjay, Lota, Amrit , Hazebroek, Mark R. , Theotokis, Pantazis , Wassall, Rebecca, Halliday, Brian P. , Tayal, Upasana , Verdonschot, Job A.J. , Marvao, Antonio de , Hammersley, Daniel , Jones, Richard, Buchan, Rachel , Noseda, Michela , Mittal, Tarun , Robertus, Jan Lukas , Vassiliou, Vassilios S. , Tzoulaki, Ioanna , Cleland, John G.F. , Barton, Paul J.R. , Cook, Stuart A. , Pennell, Dudley J. , Garcia-Pavia, Pablo , Cooper, Leslie T. , Heymans, Stéphane , Ware, James S.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10960 Get It

Background: Myocarditis may predispose to dilated cardiomyopathy (DCM) and sudden cardiac death (SCD). Familial data indicate a potential genetic susceptibility shared with arrhythmogenic cardiomyopathy (ACM). We present the first large-scale genotype-phenotype study of adults with acute myocarditis. Methods: A cohort comprising 336 consecutive patients with acute myocarditis was enrolled in London and Maastricht. All participants underwent targeted DNA sequencing for well-characterised cardiomyopathy-associated genes. The burden of rare protein altering variants (PAV) in ACM genes, DCM genes, and TTN specifically, were compared with local healthy controls sequenced on the same platform (n=1053). Case ascertainment was assessed against national hospital admission data. Results: We identified rare protein-altering variants in 23% of cases compared to 16% in controls (Δ+6.8%; p=0.021), with rare truncating variants (tv) in 6% of cases compared to <1% of controls ((Δ+5%; p=0.0097). In London (n=230; median left ventricular ejection fraction (LVEF) 63%), which was representative of national myocarditis admissions, 4.8% of cases carried rare tv, particularly within ACM genes (3% cases vs 0% controls; odds ratio 8.2; p=0.001). This was predominantly driven by desmoplakin (DSP)-tv in patients with normal LVEF. In Maastricht (n=106; median LVEF 30%), rare tv in DCM genes were enriched, particularly TTN-tv found in 7% (all with LVEF<50%) compared to 1% in controls (OR 3.6; p=0.0116). During a median follow-up of 1.9 years, all-cause mortality was greatest in those with a DCM variant (18% vs 4% with no variant; OR 5.0; p=0.004). Conclusion: We identified enrichment of cardiomyopathy gene variants in acute myocarditis patients, dominated by DSP-tv in those with normal LVEF and TTN-tv in those with reduced LVEF. Incorporation of genetic testing may be beneficial to identify such high-risk individuals and guide family screening in acute myocarditis patients.
Technical note: Evaluation and second check of a commercial Monte Carlo dose engine for small‐field apertures in pencil beam scanning proton therapy
Holmes, Jason , Shen, Jiajian , Shan, Jie , Patrick, Christopher L., Wong, William W. , Foote, Robert L. , Patel, Samir H. , Bues, Martin , Shen, Jiajian , Holmes, Jason M , Liu, Wei

Mayo Clinic

Medical Physics | March 19, 2022 | Volume: 49 | Issue: 5 | Pages: 3497-3506

10.1002/mp.15604 | PMID 35305269 Get It

Abstract Purpose To evaluate the accuracy of the RayStation Monte Carlo dose engine (RayStation MC) in modeling small‐field block apertures in proton pencil beam scanning. Furthermore, we evaluate the suitability of MCsquare as a second check for RayStation MC. Methods We have enhanced MCsquare to model block apertures. To test the accuracy of both RayStation MC and the newly enhanced MCsquare, we compare the dose predictions of each to in‐water dose measurements obtained using diode detectors and radiochromic film. Nine brass apertures with openings of 1, 2, 3, 4, and 5 cm and either 2 cm or 4 cm thickness were used in the irradiation of a water phantom. Two measurement setups were used, one with a range shifter and 119.7 MeV proton beam energy and the other with no range shifter and 147 MeV proton beam energy. To further test the validity of RayStation MC and MCsquare in modeling block apertures and to evaluate MCsquare as a second check tool, 10 small‐field (average target volume 8.3 cm 3 ) patient treatment plans were calculated by each dose engine followed by a statistical comparison. Results Comparing to the absolute dose measurements in water, RayStation MC differed by 1.2% ± 1.0% while MCsquare differed by −1.8% ± 3.7% in the plateau region of a pristine Bragg peak. Compared to the in‐water film measurements, RayStation MC and MCsquare both performed well with an average 2D‐3D gamma passing rate of 99.4% and 99.7% (3%/3 mm), respectively. A t ‐test comparing the agreement with the film measurements between RayStation MC and MCsquare suggested that the relative spatial dose distributions calculated by MCsquare and RayStation MC were statistically indistinguishable. Directly comparing the dose calculations between MCsquare and RayStation MC over 10 patients resulted in an average 3D‐3D gamma passing rates of 98.5% (3%/3 mm) and 94.1% (2%/2 mm), respectively. Conclusion The validity of RayStation MC algorithm for use with patient‐specific apertures has been expanded to include small apertures. MCsquare has been enhanced to model apertures and was found to be an adequate second check of RayStation MC in this scenario.
Connectomic analysis of unilateral dual-lead thalamic deep brain stimulation for treatment of multiple sclerosis tremor
Patel, Bhavana , Middlebrooks, Erik H. , Hilliard, Justin D. , Foote, Kelly D. , Okun, Michael S. , Okun, Michael S , Middlebrooks, Erik H , Wong, Joshua K. , Almeida, Leonardo

Mayo Clinic

Brain Communications | March 14, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac063 | PMID 35368612 Get It

Abstract Tremor is a common symptom in multiple sclerosis and can present as a severe postural and action tremor, leading to significant disability. Owing to the diffuse and progressive nature of the disease, it has been challenging to characterize the pathophysiology underlying multiple sclerosis tremor. Deep brain stimulation of the ventralis intermedius and the ventralis oralis posterior thalamic nuclei has been used to treat medically refractory multiple sclerosis tremors with variable results. The aim of this study was to characterize multiple sclerosis tremor at the network level by applying modern connectomic techniques to data from a previously completed single-centre, randomized, single-blind prospective trial of 12 subjects who were treated with unilateral dual-lead (ventralis intermedius + ventralis oralis posterior) thalamic deep brain stimulation. Preoperative T1-weighted MRI and postoperative head CTs were used, along with applied programming settings, to estimate the volume of tissue activated for each patient. The volumes of tissue activated were then used to make voxel-wise and structural connectivity correlations with clinically observed tremor suppression. The volume of the tissue-activated analyses identified the optimal region of stimulation at the ventralis oralis posterior ventralis intermedius border intersecting with the dentato-rubro-thalamic tract. A regression model showed strong connectivity to the supplemental motor area was positively associated with tremor suppression (r = 0.66) in this cohort, whereas connectivity to the primary motor cortex was negatively associated with tremor suppression (r = −0.69), a finding opposite to that seen in ventralis intermedius deep brain stimulation for essential tremor. Comparing the structural connectivity to that of an essential tremor cohort revealed a distinct network that lies anterior to the essential tremor network. Overall, the volumes of tissue activated and connectivity observations converge to suggest that optimal suppression of multiple sclerosis tremor will likely be achieved by directing stimulation more anteriorly toward the ventralis oralis posterior and that a wide field of stimulation synergistically modulating the ventralis oralis posterior and ventralis intermedius nuclei may be more effective than traditional ventralis intermedius deep brain stimulation at suppressing the severe tremors commonly seen in complex tremor syndromes such as multiple sclerosis tremor.
Abstract PD7-03: Ultra-accelerated photon, proton, and brachytherapy partial breast irradiation: Primary results of the Mayo 3-fraction trial
Mutter, Robert W. , Afzal, Arslan, Kenison, Stephanie L, Vallow, Laura A., Deufel, Christopher L. , Remmes, Nicholas B. , Ruddy, Kathryn J. , Vern-Gross, T.Z., Shumway, Dean A. , Wong, William W. , McGee, L.A. , Liu, Minetta C. , Vargas, Carlos , Visscher, Daniel W., Stish, Bradley J. , Pafundi, Deanna, Waddle, Mark R. , Golafshar, Michael A. , Halyard, Michele Y. , Corbin, Kimberly S. , Golafshar, Michael , Hieken, Tina J. , DeWees, T.A. , Boughey, Judy C. , Furutani, Keith M. , Degnim, Amy C. , Jakub, James W. , PATEL, SAMIR N. , Park, Sean S.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: PD7-03-PD7-03

10.1158/1538-7445.sabcs21-pd7-03 Get It

Abstract Background: Partial breast irradiation (PBI) is an established option for selected patients with early stage breast cancer. The optimal technique, target volume and dose/fractionation for PBI has yet to be defined. The most studied regimen in North America (38.5 Gy in 10 fractions twice daily) has been associated with cosmetic deterioration. We hypothesized that condensing treatment and reducing the total administered dose could improve the therapeutic ratio in luminal breast cancer and DCIS based on emerging evidence that breast cancer is more sensitive than surrounding normal tissues to high dose fractions. Herein, we report cosmetic, tolerability, disease control, and patient reported outcomes of a novel ultra-accelerated PBI regimen. Methods: We conducted a single arm, three cohort trial of photon, proton, and brachytherapy PBI. Technique was selected at physician and patient discretion. Eligible women were age ≥ 50 years with estrogen receptor positive (ER+), sentinel lymph node negative invasive or in-situ breast cancer measuring ≤ 2.5 cm. The regimen was designed to have comparable biologically equivalent effect as 40 Gy in 15 fractions, assuming an α/β ratio of 3.5. Intracavitary brachytherapy target volume was lumpectomy cavity plus 1 cm and prescribed 21 Gy in 3 fractions. Photon and proton target volumes were post-operative tumor bed plus 1 cm and a 3 mm setup uncertainty margin, prescribed 21.9 Gy (RBE) in 3 fractions, and delivered with image guidance. The primary outcome was the percentage difference in patients with adverse cosmesis (defined as fair or poor cosmesis) at 3 years compared to baseline pre-PBI, as assessed by trained nurses using the 4-point Harvard breast cosmesis scale. Patients also completed quality of life surveys and self-reported cosmesis using the 4-point scale. Locoregional and distant recurrence-free survival was determined using the Kaplan-Meier method. Adverse events were assessed using CTCAE, v 4.0. Results: Between 2015 and 2017, 163 patients were treated: photons in 58, protons in 48, and brachytherapy in 57. Median patient age was 66 years. 129 (79%) patients had invasive breast cancer (all ER+) and 34 (21%) had DCIS (83% ER+). Median tumor size was 1.1 cm. Grade was 2-3 in 102 (63%). The median mean heart/ipsilateral lung doses were photons 0.1/1.6 Gy, protons &lt;0.001/0.1 Gy, and brachytherapy 0.5/0.9 Gy. Median follow-up was 4.1 years (IQR 3.9-5.0). The proportion of patients with adverse cosmesis (by RN assessment) was 14.3% at baseline and 3.8% at 3 years, with four patients (1 photon, 1 proton, 2 brachytherapy) experiencing cosmetic deterioration at 3 years from baseline. The proportion with adverse cosmesis by self-report at 3 years was 2.4%, with three patients (1 photon, 1 proton, 1 brachytherapy) reporting cosmetic deterioration. Four patients developed locoregional recurrence (1 photons, 2 protons, 1 brachytherapy); three were local only and one was local and distant. 4-year locoregional recurrence and distant metastasis-free survival were 97.9% and 97.4%, respectively. There were 2 treatment related ≥ grade 2 late events (grade 2 fibrosis and grade 2 seroma, both brachytherapy associated), and no evidence of deterioration in patient-reported pain, fatigue, breast related or overall quality of life, as assessed by the patient reported outcomes version of the CTCAE, 10-point linear analog scales, and the breast cancer treatment outcomes scale. Conclusions: Ultra-accelerated 3-fraction PBI exquisitely spared normal tissues and was associated with favorable cosmetic outcomes, disease control, and excellent long-term tolerability. This ‘precision-radiotherapy’ approach may optimize the therapeutic ratio over more aggressive radiotherapy options as well as radiotherapy omission, particularly in patients with long life expectancies. Citation Format: Robert Mutter, Tina Hieken, Todd DeWees, Arslan Afzal, Stephanie Kenison, Laura Vallow, Christopher Deufel, Nicholas Remmes, Kathryn Ruddy, Judy Boughey, Keith Furutani, Amy Degnim, James Jakub, Tamara Vern-Gross, Dean Shumway, William Wong, Samir Patel, Lisa McGee, Minetta Liu, Carlos Vargas, Daniel Visscher, Bradley Stish, Deanna Pafundi, Mark Waddle, Michael Golafshar, Michele Halyard, Kimberly Corbin, Sean Park. Ultra-accelerated photon, proton, and brachytherapy partial breast irradiation: Primary results of the Mayo 3-fraction trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD7-03.
CD38 inhibitor 78c increases mice lifespan and healthspan in a model of chronological aging
Thompson, Katie L., Warner, Gina M., Chini, Claudia C.S. , Tarragó, Mariana G., Mazdeh, Delaram Z., Zhang, Chunlian , Zavala‐Solorio, Jose , Kolumam, Ganesh , Wong, Yao Liang , Cohen, Robert L. , Chini, Eduardo N. , Peclat, Thais R , Liang Wong, Yao , Chini, Eduardo Nunes , Peclat, Thais

Mayo Clinic

Aging Cell | March 8, 2022 | Volume: 21 | Issue: 4 | Pages: No page available

10.1111/acel.13589 | PMID 35263032 Get It

Abstract Nicotinamide adenine dinucleotide (NAD) levels decline during aging, contributing to physical and metabolic dysfunction. The NADase CD38 plays a key role in age‐related NAD decline. Whether the inhibition of CD38 increases lifespan is not known. Here, we show that the CD38 inhibitor 78c increases lifespan and healthspan of naturally aged mice. In addition to a 10% increase in median survival, 78c improved exercise performance, endurance, and metabolic function in mice. The effects of 78c were different between sexes. Our study is the first to investigate the effect of CD38 inhibition in naturally aged animals.
Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601.
Chan, Emily , Pugh, Stephanie L. , Simko, Jeff, Feng, Felix Y. , Shipley, William U. , Lukka, Himanshu, Bahary, Jean-Paul , Pisansky, Thomas M. , Zeitzer, Kenneth L. , Lawton, C.A., Balogh, Alexander G., Lovett, R.D., Wong, Anthony , Dess, Robert T. , McGinnis, Scott, Kuettel, Michael, DeMora, Lyudmila, Dess, Robert T , Efstathiou, Jason A. , Rosenthal, Seth A. , McGinnis, Scott, Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 265-265

10.1200/jco.2022.40.6_suppl.265 Get It

265 Background: A recent study ( Fossati et al, 2018) found that higher lymph node count at radical prostatectomy was associated with improved outcomes in patients treated with salvage radiation for elevated prostate-specific antigen (PSA) after surgery. We sought to validate these results in NRG/RTOG 9601, a randomized controlled trial of men with pT2/T3 disease who underwent either radiation (RT) alone or RT+antiandrogen (bicalutamide) therapy for PSA elevation following radical prostatectomy from 1998-2003. Methods: We reviewed available pathology reports for all patients in NRG/RTOG 9601 to determine the nodal count at radical prostatectomy. Clinical data was as of 11/5/2015, same as the primary endpoint for the trial. Cox proportional hazards models were used to assess the effect of number of positive lymph nodes, treatment arm (RT alone or RT+bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease specific survival. Results: Out of the 760 patients originally eligible in the trial, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range 0-33, Q1-Q3 3-9). There were no significant differences between treatment arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm (RT alone vs RT+bicalutamide median 5 vs 6, p = 0.11). There was no significant association between total lymph nodes and overall survival with both arms combined (HR = 1.00, 95% CI:0.97-1.03, p = 0.87) or in the individual arms alone (RT+Casodex: HR = 1.01, 95% CI:0.97-1.05, p = 0.65; RT+Placebo: HR = 0.98, 95% CI: 0.94-1.03, p = 0.45). There was also no significant association between total lymph nodes and disease-specific survival with both arms combined (HR = 1.00, 95% CI:0.95-1.04, p = 0.84) and in the arms alone (RT+Casodex: HR = 1.00, 95% CI:0.95-1.05, p = 0.92; RT+Placebo: HR = 0.99, 95% CI: 0.92-1.07, p = 0.86). In multivariable analysis performed on the two arms, Gleason score was the only feature associated with worse overall and disease-specific survival, seen only in the RT alone arm. Similar findings were seen when evaluating times to local and distant failure. Conclusions: Lymph node yield in NRG/RTOG 9601 did not show any association with adverse outcomes in the entire cohort, or in either treatment arm alone. The therapeutic benefit of an extensive lymph node dissection in this population remains uncertain. Clinical trial information: NCT00002874.